某三甲综合医院平均住院日的影响因素及对策探讨

目的：了解盐城市某三甲医院2016—2018年平均住院日情况，对三年未达院部指标的科室进行原因分析，提出缩短平均住院日的有效对策。方法：收集某三甲医院2016—2018年各临床科室平均住院日数据，进行横向和纵向比较，与院部每年设定的科室平均住院日标准比较，查找三年未达标的和影响医院平均住院日较大的临床科室；运用问卷调查，找出影响平均住院日较大的医技科室；另外院部指令对缩短平均住院日有监管责任的职能科室，进行PDCA持续改进平均住院日。结果：经过全院各科室全员参与讨论，找到影响医院平均住院日的主要原因有入院、出院标准把控不严，医疗技术水平不够，医技检查等候时间长，未完全建立与基层、社区医院的转诊机制。结论：各科室运用PDCA管理工具进行持续改进，针对影响本科室平均住院日的主要原因采取有效对策，如加强核心制度的落实，不断提高医疗技术，开展新技术；加强患者住院期的管理；畅通医院与基层、社区转诊渠道；外科手术患者术前安排在门诊检查；缩短医技科室检查等候时间等。     

Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup

Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients.     

Relationship between tRNA-derived fragments and human cancers

tRNA-derived fragments, a class of small noncoding RNAs (sncRNAs), have been identified in numerous studies in recent years. tRNA-derived fragments are classified into two main groups, including tRNA halves (tiRNAs) and tRNA-derived small RNA fragments (tRFs), according to different cleavage positions of the precursor or mature tRNAs. Instead of random tRNA degradation debris, a growing body of evidence has shown that tRNA-derived fragments are precise products of specific tRNA modifications and play important roles in biological activities, such as regulating protein translation, affecting gene expression, and altering immune signaling. Recently, the relations between tRNA-derived fragments and the occurrence of human diseases, especially cancers, have generated wide interest. It has been demonstrated that tRNA-derived fragments are involved in cancer cell proliferation, metastasis, progression and survival. In this review, we will describe the biogenesis of tRNA-derived fragments, the distinct expression and function of tRNA-derived fragments in the development of cancers, and their emerging roles as diagnostic and prognostic biomarkers and precise targets of future treatments.     

针对目前已注册的上市中成药治疗新型冠状病毒肺炎临床研究分析＊

本研究系统分析了中成药治疗新型冠状病毒肺炎临床研究方案注册信息，以提高相关临床研究设计质量，以及为中成药上市后评价提供参考和建议。对中国临床试验注册中心网站（www.chictr.org.cn）和美国临床试验注册中心网站（clinicaltrials.gov）进行检索，以新型肺炎、COVID-19、中成药等为检索词，检索新型冠状病毒肺炎中成药相关临床研究方案。按照纳排标准筛选临床研究，并提取注册号、研究题目、研究设计及类型、干预措施等数据，采用描述性分析方法对纳入研究的注册信息进行分析。共纳入新型冠状病毒肺炎中成药相关研究方案35个，其中涉及的8种中成药是新冠肺炎诊疗方案（第七版）中所推荐使用的药物。评价的干预措施共涉及23种中成药（如血必净注射液、喜炎平注射液、连花清瘟胶囊/颗粒等）。主要疗效指标以退热时间、疾病痊愈时间/有效率等为主。结果显示：中成药治疗新冠肺炎的临床研究响应快速，目前已注册多个临床研究，包括疾病诊治、预防全过程。但也存在问题，如研究人群不明确、评价指标代表性差等，相关研究设计和实施尚有待优化，以进一步提高临床试验研究的可行性，以期为当前和后续更多的临床研究方案提供参考。     

心脑宁胶囊治疗动脉粥样硬化性心血管疾病临床应用专家共识

本共识建立了成人动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)高危人群规范应用心脑宁胶囊以提升疗效的关键流程,概述了心脑宁胶囊的中医配伍理论、药学和药理研究特性,界定了心脑宁胶囊的精确适用人群、干预时机、病证疗效特点及优选应用方案,归纳了心脑宁胶囊的不良反应、使用禁忌、注意事项及非临床安全性等相关证据。本共识适合ASCVD相关专业领域的执业医师、执业中医医师和执业中西医结合医师使用。     

完全腹腔镜下与开腹胰十二指肠切除术治疗壶腹周围肿瘤近期疗效比较

目的探讨完全腹腔镜下胰十二指肠切除术(TLPD)与开腹胰十二指肠切除术(OPD)治疗壶腹周围肿瘤的近期疗效。方法回顾性分析山西医科大学第一医院2016年6月至2019年3月收治的50例壶腹周围肿瘤患者的临床资料,根据手术方式不同分为TLPD组(22例)及OPD组(28例),比较两组患者围术期及术后各项指标情况。结果两组患者均顺利完成手术,TLPD组手术时间[(665±213)min]长于OPD组[(447±215)min],差异有统计学意义(t=-0.356,P=0.001);TLPD组术中出血量[100 ml(50~325 ml)]少于OPD组[300 ml(100~500 ml)],差异有统计学意义(Z=-2.230,P=0.026)。TLPD组与OPD组术中输血者比例、淋巴结清扫数量、切除肿瘤长径、术后禁饮食时间、术后拔管时间、术后住院时间及术后并发症发生率比较,差异均无统计学意义(均P>0.05)。结论TLPD与OPD治疗壶腹周围肿瘤临床近期疗效相近,TLPD手术时间较OPD长,但可有效控制术中出血量。     

磷酸酯单体媒介的氧化锆陶瓷与树脂粘接的耐水性评价

目的：评价2种含磷酸酯单体的底涂剂处理的Y?TZP陶瓷与树脂的粘接及其耐水解性。方法：80枚氧化锆（Y?TZP）瓷片随机分为4组进行不同的表面处理：氧化铝喷喷砂；氧化铝喷砂后以氧化锆底涂剂Z?Prime Plus或Clearfil Ceramic Prime处理；摩擦化学法硅涂层后以硅烷处理。使用树脂水门汀制作粘接试件测试其剪切粘接强度。Y?TZP瓷片表面分别经过2种底涂剂处理后以X射线光电子能谱分析（XPS）检测其表面化学键变化。采用电感耦合等离子体制谱（ICP?MS）测试Y?TZP/树脂粘接界面的磷元素释放量。结果：老化前，与阴性对照组相比，2种含MDP的底涂剂处理均能提高短期粘接强度值，但硅涂层处理组的粘接强度最高。老化后，硅涂层处理组较老化前未有明显变化；喷砂及2种含MDP底涂剂处理组的粘接强度值显著下降（P < 0.05）。XPS在Y?TZP陶瓷使用2种含MDP底涂剂处理后均检测出“?P?O?Zr”键。ICP?MS测试在使用含MDP底涂剂处理的粘接试件的浸泡液中检测到磷元素的释放。结论：水会负面影响磷酸酯单体介导的氧化锆与树脂间的粘接。